SCHEMBL6469092

SCHEMBL6469092

CC(O)CC(C)c1ccc(C(N)=O)nc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.41
SIRT6 Q8N6T7 2/20 0.36
P4HTM Q9NXG6 1/20 0.35
NAMPT P43490 1/20 0.35
VNN1 O95497 1/20 0.34
HRH3 Q9Y5N1 2/20 0.33
TLR8 Q9NR97 1/20 0.33
TLR7 Q9NYK1 1/20 0.33
ESR1 P03372 1/20 0.33
ESR2 Q92731 1/20 0.33
NNMT P40261 1/20 0.33
APP P05067 1/20 0.33
ADORA3 P0DMS8 1/20 0.33
TSHR P16473 1/20 0.33
MC4R P32245 1/20 0.33
ADRA1A P35348 1/20 0.33
MC3R P41968 1/20 0.33
PDE4A P27815 1/20 0.32
PDE4B Q07343 1/20 0.32
PDE4C Q08493 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6468851 0.88 KMT2A (0.41) KMT2ASIRT6P4HTMNAMPTVNN1
SCHEMBL2677914 0.84 ALDH1A1 (0.44) KMT2ASIRT6P4HTMTSHRNPC1
SCHEMBL6469024 0.84 KMT2A (0.39) KMT2ASIRT6P4HTMNAMPTVNN1
SCHEMBL6469006 0.82 KMT2A (0.47) KMT2ASIRT6P4HTMNAMPTHRH3
SCHEMBL5040340 0.81 KMT2A (0.41) KMT2ASIRT6P4HTMNAMPTVNN1
SCHEMBL8953636 0.80 KMT2A (0.49) KMT2ASIRT6P4HTMNAMPTHRH3
SCHEMBL5040582 0.79 KMT2A (0.35) KMT2ASIRT6P4HTMNAMPTVNN1
SCHEMBL6650658 0.79 KMT2A (0.45) KMT2ASIRT6P4HTMNAMPTHRH3
SCHEMBL5037523 0.77 KMT2A (0.43) KMT2ASIRT6NAMPTVNN1GRM2
SCHEMBL6470782 0.77 KMT2A (0.43) KMT2ASIRT6NAMPTVNN1GRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050107381-A1 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders PFIZER, INC. 2005-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107381-A1 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders APP, BACE1, SNCA KMT2A 2085/4885SIRT6 750/4885P4HTM 3028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.